JOP20240024A1 - صياغات الأجسام المضادة - Google Patents

صياغات الأجسام المضادة

Info

Publication number
JOP20240024A1
JOP20240024A1 JOJO/P/2024/0024A JOP20240024A JOP20240024A1 JO P20240024 A1 JOP20240024 A1 JO P20240024A1 JO P20240024 A JOP20240024 A JO P20240024A JO P20240024 A1 JOP20240024 A1 JO P20240024A1
Authority
JO
Jordan
Prior art keywords
antibody formulations
exemplary embodiments
composition comprises
liquid composition
liquid
Prior art date
Application number
JOJO/P/2024/0024A
Other languages
Arabic (ar)
English (en)
Inventor
Nicole Ball
Christopher Sloey
Rulin Qian
Alexis Lueras
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20240024A1 publication Critical patent/JOP20240024A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JOJO/P/2024/0024A 2021-08-12 2024-02-08 صياغات الأجسام المضادة JOP20240024A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163232299P 2021-08-12 2021-08-12
US202263316604P 2022-03-04 2022-03-04
PCT/US2022/040056 WO2023018870A1 (en) 2021-08-12 2022-08-11 Antibody formulations

Publications (1)

Publication Number Publication Date
JOP20240024A1 true JOP20240024A1 (ar) 2024-02-08

Family

ID=83151728

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0024A JOP20240024A1 (ar) 2021-08-12 2024-02-08 صياغات الأجسام المضادة

Country Status (16)

Country Link
US (1) US20240343795A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384217A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532736A (cg-RX-API-DMAC7.html)
KR (1) KR20240046881A (cg-RX-API-DMAC7.html)
AU (1) AU2022325870A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228269A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000401A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024001383A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240130A (cg-RX-API-DMAC7.html)
IL (1) IL310275A (cg-RX-API-DMAC7.html)
JO (1) JOP20240024A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001934A (cg-RX-API-DMAC7.html)
PE (1) PE20240650A1 (cg-RX-API-DMAC7.html)
TW (1) TW202319398A (cg-RX-API-DMAC7.html)
UY (1) UY39896A (cg-RX-API-DMAC7.html)
WO (1) WO2023018870A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026062214A1 (en) * 2024-09-19 2026-03-26 Sanofi Formulations comprising lunsekimig

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
EP3472202A1 (en) 2016-06-15 2019-04-24 Amgen Inc. Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease
EP3824906A1 (en) * 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
PL3615066T3 (pl) 2017-04-28 2024-04-29 Amgen Inc. Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania
US12103979B2 (en) * 2017-04-28 2024-10-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
WO2021079337A1 (en) * 2019-10-23 2021-04-29 Cadila Healthcare Limited Pharmaceutical formulation of anti-her2 antibody and preparation thereof

Also Published As

Publication number Publication date
IL310275A (en) 2024-03-01
WO2023018870A1 (en) 2023-02-16
MX2024001934A (es) 2024-03-04
CA3228269A1 (en) 2023-02-16
US20240343795A1 (en) 2024-10-17
TW202319398A (zh) 2023-05-16
PE20240650A1 (es) 2024-04-04
JP2024532736A (ja) 2024-09-10
KR20240046881A (ko) 2024-04-11
EP4384217A1 (en) 2024-06-19
CO2024001383A2 (es) 2024-03-07
CL2024000401A1 (es) 2024-06-21
AU2022325870A1 (en) 2024-02-08
CR20240130A (es) 2024-04-12
UY39896A (es) 2023-02-28

Similar Documents

Publication Publication Date Title
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
SA521430342B1 (ar) تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري
EA201200204A1 (ru) Содержащая антитело к her2 композиция для подкожного введения
EA202193240A1 (ru) Стабилизированные составы, содержащие анти-angptl3 антитела
EA201792552A1 (ru) Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20
RU2013137740A (ru) Жидкая композиция, содержащая антитело высокой концентрации
ECSP077261A (es) Composición de anticuerpo her2
PE20061043A1 (es) Composicion farmaceutica que comprende anticuerpos monoclonales
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
MX2021007393A (es) Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf.
AR117652A1 (es) Composiciones farmacéuticas que comprenden conjugados de anticuerpo anti-191p4d12 y fármaco y métodos de usarlas
UY38153A (es) Formulaciones acuosas estables de anticuerpos anti-tau
UY39878A (es) Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma
MX2022010217A (es) Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.
FR3069155B1 (fr) Composition comprenant une concentration elevee en lipopeptides ituriniques
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
MX2025005954A (es) Composicion del conjugado anticuerpo anti-her3-farmaco y uso farmaceutico de la misma
MX2024001934A (es) Formulaciones de anticuerpos.
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
MX2023014616A (es) Formulaciones de anticuerpos anti-pd1.
BR112022022620A2 (pt) Formulações de anticorpos anti-il-33
JOP20240028A1 (ar) جسيمات شحمية تتضمن ببتيدات تاو الفسفورية لتحفيز الاستجابات المناعية المستدامة